Blog
RSS FeedPosted by Michael Wonder on 06 Nov 2024
Avapritinib for the treatment of patients with advanced systemic mastocytosis
6 November 2024 - NICE has published evidence-based recommendations on the use of avapritinib (Ayvakyt) for the treatment of adults ...
Posted by Michael Wonder on 06 Nov 2024
Fenfluramine hydrochloride for the treatment of patients 2 years of age and older with seizures associated with Lennox–Gastaut syndrome
5 November 2024 - Following an appeal, NICE has published further draft guidance on the use of using fenfluramine hydrochloride ...
Posted by Michael Wonder on 31 Oct 2024
Sugemalimab approved to treat adult patients with non-small cell lung cancer
30 October 2024 - The MHRA has today approved sugemalimab (Eqjubi) to treat adult patients with non-small cell lung cancer. ...
Posted by Michael Wonder on 31 Oct 2024
Leniolisib phosphate for the treatment of patients 12 years of age and older with activated phosphoinositide 3-kinase delta syndrome
31 October 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 30 Oct 2024
Osimertinib mesylate in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with advanced EGFR mutation positive non-small-cell lung cancer
30 October 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 30 Oct 2024
Eplontersen for the treatment of patients with hereditary transthyretin related amyloidosis
29 October 2024 - NICE has published final drat guidance on the use of eplontersen for the treatment of patients ...
Posted by Michael Wonder on 29 Oct 2024
People with a rare form of blood cancer are set to benefit after NICE recommends new targeted therapy
29 October 2024 - Hundreds of people with a rare form of blood cancer could be set to benefit after NICE ...
Posted by Michael Wonder on 24 Oct 2024
Driving down the cost of biologics: lessons from a nationalised health care system
18 October 2024 - Few treatments have revolutionised care for people with chronic inflammatory disorders more than biologic and small molecule ...
Posted by Michael Wonder on 24 Oct 2024
Quizartinib dihydrochloride for the induction, consolidation and maintenance treatment of adults with newly diagnosed FLT3-ITD positive acute myeloid leukaemia
23 October 2024 - NICE has published final evidence-based recommendations on the use of quizartinib dihydrochloride (Vanflyta) for the induction, ...
Posted by Michael Wonder on 23 Oct 2024
Lilly's Kisunla (donanemab-azbt) receives marketing authorisation in Great Britain for the treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease in adult patients who are apolipoprotein E Ε4 heterozygotes or non-carriers
23 October 2024 - Donanemab was first approved in the United States in July 2024 and then approved in Japan ...
Posted by Michael Wonder on 23 Oct 2024
New Alzheimer’s treatment donanemab does not currently demonstrate value for the NHS says NICE
23 October 2024 - More evidence is needed on the clinical and cost effectiveness of donanemab, a new treatment for mild ...
Posted by Michael Wonder on 23 Oct 2024
Danicopan in combination with ravulizumab or eculizumab for the treatment of patients with paroxysmal nocturnal haemoglobinuria (final guidance)
23 October 2024 - NICE has published final evidence-based recommendations on the use of danicopan (Voydeya) in combination with ravulizumab ...
Posted by Michael Wonder on 17 Oct 2024
First targeted treatment to reduce the risk of ALK positive lung cancer returning after complete tumour removal recommended by NICE
17 October 2024 - For the first time, NICE has recommended a targeted treatment option for ALK positive non-small-cell lung cancer, ...
Posted by Michael Wonder on 17 Oct 2024
Eplontersen approved to treat adults with rare inherited nerve disease or polyneuropathy
16 October 2024 - The MHRA has approved eplontersen (Wainzua) to treat adults with polyneuropathy associated with hereditary transthyretin amyloidosis, which ...
Posted by Michael Wonder on 09 Oct 2024
Elafibranor approved as first medicine to treat adults with a rare liver disease known as primary biliary cholangitis
8 October 2024 - The MHRA has approved elafibranor (Iqirvo) to treat adult patients with a rare type of liver disease ...